MedTrace Logo

Biomarkers for Risk Stratification After STEMI

NCT03735719 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 136

Last updated 2019-10-01

No results posted yet for this study

Summary

Despite modern reperfusion strategies, myocardial infarction leads to deleterious processes resulting in left ventricular remodelling (LVR) and heart failure (HF). Several biomarkers i.e. galectin-3 (Gal-3) and soluble ST-2 protein are involved in LVR as a result of inflammatory processes and fibrosis. There is an evidence of a high prognostic value of both biomarkers in prediction of outcomes in HF patients. This study will further investigate the role of Gal-3 and ST-2 in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) and without prior HF in prediction of unfavourable outcomes.

Conditions

Sponsors & Collaborators

  • Medical University of Warsaw

    lead OTHER

Principal Investigators

  • Agnieszka Kapłon-Cieślicka, PhD · 1st Chair and Department of Cardiology, Medical University of Warsaw

  • Grzegorz Opolski, Professor · 1st Chair and Department of Cardiology, Medical University of Warsaw

  • Krzysztof J Filipiak, Professor · 1st Chair and Department of Cardiology, Medical University of Warsaw

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2018-05-31
Completion
2021-01-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03735719 on ClinicalTrials.gov